---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-071386"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-08-21T23:59:59+00:00"
generated_at: "2026-05-31T08:16:49.497682+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InMed Pharma issued 3 US patents for EB treatment, biosynthesis, ocular delivery

## Summary
- Patent for INM-755 cannabinoid topical for epidermolysis bullosa granted in US, Australia, Japan, Israel.
- Biosynthesis patent for manufacturing proprietary analogs granted in US, issued Sept 3, 2024.
- Ocular drug delivery formulation patent granted/allowed in US, Europe, Australia, Japan, India.
- Total IP portfolio now 13 patent families covering NCEs, formulations, manufacturing, methods of use.
- Company continues pursuing patent protection for INM-901 (Alzheimer's) and INM-089 (dry AMD).

## SEC filing metadata
- accession: 0001213900-24-071386
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/0001213900-24-071386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/ea0212056-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-071386
- JSON: https://secwatch.observer/filing/0001213900-24-071386.json
- Plain text: https://secwatch.observer/filing/0001213900-24-071386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.